Trial Profile
A Long-Term Follow-Up Study in Subjects Who Received an Adenovirus-Associated Viral Vector Serotype 2 Containing the Human RPE65 Gene (AAV2-hRPE65v2, Voretigene Neparvovec-rzyl) Administered Via Subretinal Injection
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Voretigene neparvovec (Primary)
- Indications Leber congenital amaurosis
- Focus Therapeutic Use
- Sponsors Spark Therapeutics
- 31 Jul 2018 New trial record